{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:00:55Z","timestamp":1784869255451,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of conventional transarterial chemoembolization (cTACE) using a glass membrane emulsification device (GMD) versus a three-way stopcock (3WS) in treatment-na\u00efve target lesions of hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 54 patients (73 target lesions) treated with GMD-cTACE and 39 patients (55 target lesions) treated with 3WS-cTACE. The emulsion consisted of 5 mL of Lipiodol and 2.5 mL of an iodinated nonionic contrast medium (iomeprol 300\u00a0mg I\/mL) containing 50\u00a0mg of epirubicin. The primary endpoints were the direct treatment effect on target lesions, assessed by RECICL (2015). Recurrence-free survival (RFS), safety and modified albumin\u2013bilirubin (mALBI) grade changes were evaluated as secondary endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TE4 rates were 86.3% in the GMD group and 76.4% in the 3WS group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.15). The combined TE4\u2009+\u2009TE3 rates were 93.2% versus 83.6%, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.09). The median RFS of target lesions was 1,047 days in the GMD group and 362 days in the 3WS group. RFS of target lesions tended to be longer with GMD (log-rank\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.058), with 1-year RFS estimates of 0.740 (GMD) and 0.470 (3WS). Restricted mean survival time (RMST) up to 365 days favored GMD (difference, 40.2 days; 95% CI, \u2212\u20090.8 to 81.1;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.054). Changes in hepatic reserve were not significantly different between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GMD-cTACE showed numerically longer RFS of target lesions than 3WS-cTACE, with no significant between-group difference in hepatic function deterioration. Standardizing emulsion quality with GMD may improve the durability of local control in cTACE; larger prospective studies are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-026-01995-7","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:33:55Z","timestamp":1778049235000},"page":"1468-1476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of conventional transarterial chemoembolization for hepatocellular carcinoma using a glass membrane emulsification device: comparison with a three-way stopcock"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3117-9720","authenticated-orcid":false,"given":"Yusuke","family":"Ono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Satomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Tomotake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Koretsune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaishu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1995_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1148\/radiology.154.1.2981114","volume":"154","author":"H Ohishi","year":"1985","unstructured":"Ohishi H, Uchida H, Yoshimura H, Ohue S, Ueda J, Katsuragi M, Matsuo N, et al. Hepatocellular carcinoma detected by iodized oil: use of anticancer agents. Radiology. 1985;154:25\u20139.","journal-title":"Radiology"},{"key":"1995_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1148\/radiology.170.3.2536946","volume":"170","author":"H Nakamura","year":"1989","unstructured":"Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989;170:783\u20136.","journal-title":"Radiology"},{"key":"1995_CR3","doi-asserted-by":"publisher","DOI":"10.22575\/interventionalradiology.2023-0009","author":"H Higashihara","year":"2025","unstructured":"Higashihara H, Kimura Y, Ono Y, Tanaka K, Tomiyama N. Effective utilization of conventional transarterial chemoembolization and drug-eluting bead transarterial chemoembolization in hepatocellular carcinoma: a guide to proper usage. Interventional Radiol. 2025. https:\/\/doi.org\/10.22575\/interventionalradiology.2023-0009.","journal-title":"Interventional Radiol"},{"key":"1995_CR4","doi-asserted-by":"publisher","first-page":"e20220035","DOI":"10.22575\/interventionalradiology.2022-0035","volume":"10","author":"K Yamakado","year":"2023","unstructured":"Yamakado K, Takaki H. The new updated barcelona clinic liver cancer staging system: roles of trans-arterial chemoembolization and homework to interventional radiologists. Interv Radiol (Higashimatsuyama). 2023;10:e20220035. https:\/\/doi.org\/10.22575\/interventionalradiology.2022-0035.","journal-title":"Interv Radiol (Higashimatsuyama)"},{"issue":"25","key":"1995_CR5","doi-asserted-by":"publisher","first-page":"02571","DOI":"10.1016\/j.jhep.2025.10.020","volume":"S0168\u20138278","author":"M Reig","year":"2025","unstructured":"Reig M, Sanduzzi-Zamparelli M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2025 update. J Hepatol. 2025;S0168\u20138278(25):02571\u20131. https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020.","journal-title":"J Hepatol"},{"key":"1995_CR6","doi-asserted-by":"publisher","DOI":"10.22575\/interventionalradiology.2024-0016","author":"T Tanaka","year":"2024","unstructured":"Tanaka T. Transarterial chemoembolization for hepatocellular carcinoma: current role and techniques. Interventional Radiol. 2024. https:\/\/doi.org\/10.22575\/interventionalradiology.2024-0016.","journal-title":"Interventional Radiol"},{"issue":"12","key":"1995_CR7","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00270-017-1763-5","volume":"40","author":"F Deschamps","year":"2017","unstructured":"Deschamps F, Moine L, Isoardo T, Tselikas L, Paci A, Mir LM, et al. Parameters for stable water-in-oil lipiodol emulsion for liver TACE. Cardiovasc Intervent Radiol. 2017;40(12):1927\u201332.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"1995_CR8","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jvir.2018.03.027","volume":"29","author":"MK He","year":"2018","unstructured":"He MK, Zou RH, Wei W, Shen JX, Zhao M, Zhang YF, et al. Comparison of stable and unstable ethiodized oil emulsions for transarterial chemoembolization of hepatocellular carcinoma: results of a single-center double-blind prospective randomized controlled trial. J Vasc Interv Radiol. 2018;29(8):1068\u2013e10772.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"1995_CR9","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s00330-017-5197-x","volume":"28","author":"T Tanaka","year":"2018","unstructured":"Tanaka T, Masada T, Nishiofuku H, Fukuoka Y, Sato T, Tatsumoto S, et al. Development of pumping emulsification device with glass membrane to form ideal lipiodol emulsion in transarterial chemoembolization. Eur Radiol. 2018;28(5):2203\u20137.","journal-title":"Eur Radiol"},{"issue":"1","key":"1995_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00270-019-02311-9","volume":"43","author":"T Tanaka","year":"2020","unstructured":"Tanaka T, Nishiofuku H, Masada T, Fukuoka Y, Sato T, Tatsumoto S, et al. Drug release property of lipiodol emulsion formed by glass-membrane device for transarterial chemoembolization. Cardiovasc Intervent Radiol. 2020;43(1):135\u20139.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"1995_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jvir.2019.06.015","volume":"31","author":"T Masada","year":"2020","unstructured":"Masada T, Tanaka T, Nishiofuku H, Fukuoka Y, Taiji R, Sato T, et al. Use of a glass membrane pumping emulsification device improves systemic and tumor pharmacokinetics in rabbit VX2 liver tumor in transarterial chemoembolization. J Vasc Interv Radiol. 2020;31(2):347\u201351.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"1995_CR12","doi-asserted-by":"publisher","first-page":"5817","DOI":"10.21873\/anticanres.15399","volume":"41","author":"N Imai","year":"2021","unstructured":"Imai N, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, et al. Safety and efficacy of glass membrane pumping emulsification device in transarterial chemoembolization for hepatocellular carcinoma: first clinical outcomes. Anticancer Res. 2021;41(11):5817\u201320.","journal-title":"Anticancer Res"},{"issue":"8","key":"1995_CR13","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.21873\/anticanres.15889","volume":"42","author":"N Imai","year":"2022","unstructured":"Imai N, Ishigami M, Oie Y, Kumagai M, Inukai Y, Yokoyama S, et al. Effectiveness of porous glass membrane pumping emulsification device in transarterial chemoembolization for solitary hepatocellular carcinoma. Anticancer Res. 2022;42(8):3947\u201351.","journal-title":"Anticancer Res"},{"issue":"3","key":"1995_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.21037\/apm-22-1048","volume":"12","author":"T Ishikawa","year":"2023","unstructured":"Ishikawa T, Kodama E, Kobayashi T, Azumi M, Nozawa Y, Iwanaga A, et al. Efficacy of glass membrane emulsification device in conventional transarterial chemoembolization for hepatocellular carcinoma: a preliminary study. Ann Palliat Med. 2023;12(3):448\u201357.","journal-title":"Ann Palliat Med"},{"issue":"1","key":"1995_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hepr.12542","volume":"46","author":"M Kudo","year":"2016","unstructured":"Kudo M, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Imai I, et al. Response evaluation criteria in cancer of the liver (RECICL) (2015 Revised version). Hepatol Res. 2016;46(1):3\u20139.","journal-title":"Hepatol Res"},{"issue":"6","key":"1995_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1159\/000530441","volume":"12","author":"K Asano","year":"2023","unstructured":"Asano K, Kageyama K, Yamamoto A, Jogo A, Uchida-Kobayashi S, Sohgawa E, et al. Transcatheter arterial chemoembolization for treatment-naive hepatocellular carcinoma has different treatment effects depending on central or peripheral tumor location. Liver Cancer. 2023;12(6):576\u201389.","journal-title":"Liver Cancer"},{"issue":"10","key":"1995_CR17","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jvir.2017.03.032","volume":"28","author":"T Masada","year":"2017","unstructured":"Masada T, Tanaka T, Nishiofuku H, Fukuoka Y, Sato T, Tatsumoto S, et al. Techniques to form a suitable lipiodol-epirubicin emulsion by using 3-way stopcock methods in transarterial chemoembolization for liver tumor. J Vasc Interv Radiol. 2017;28(10):1461\u20136.","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"1995_CR18","doi-asserted-by":"publisher","first-page":"e115898","DOI":"10.1371\/journal.pone.0115898","volume":"9","author":"JW Choi","year":"2014","unstructured":"Choi JW, Cho HJ, Park JH, Baek SY, Chung JW, Kim DD, et al. Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse lipiodol emulsions and drug-eluting beads. PLoS ONE. 2014;9(12):e115898.","journal-title":"PLoS ONE"},{"key":"1995_CR19","doi-asserted-by":"publisher","first-page":"101143","DOI":"10.1016\/j.jddst.2019.101143","volume":"53","author":"E Ahnfelt","year":"2019","unstructured":"Ahnfelt E, Degerstedt O, Lilienberg E, Sj\u00f6gren E, Hansson P, Lennern\u00e4s H. Lipiodol-based emulsions used for transarterial chemoembolization and drug delivery: effects of composition on stability and product quality. J Drug Deliv Sci Technol. 2019;53:101143. https:\/\/doi.org\/10.1016\/j.jddst.2019.101143.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1995_CR20","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1148\/radiology.201.3.8939223","volume":"201","author":"T de Baere","year":"1996","unstructured":"de Baere T, Zhang X, Aubert B, Harry G, Lagrange C, Ropers J, et al. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology. 1996;201:731\u20135.","journal-title":"Radiology"},{"key":"1995_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1076-6332(97)80029-3","volume":"4","author":"Z Kan","year":"1997","unstructured":"Kan Z, Wright KC, Wallace S. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models. Acad Radiol. 1997;4:275\u201382.","journal-title":"Acad Radiol"},{"key":"1995_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s002700010070","volume":"23","author":"H Demachi","year":"2000","unstructured":"Demachi H, Matsui O, Abo H, Tatsu H. Simulation model based on non-Newtonian fluid mechanics applied to the evaluation of the embolic effect of emulsions of iodized oil and anticancer drug. Cardiovasc Intervent Radiol. 2000;23:285\u201390.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"1995_CR23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.critrevonc.2013.07.003","volume":"88","author":"JM Id\u00e9e","year":"2013","unstructured":"Id\u00e9e JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013;88(3):530\u201349.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"1995_CR24","first-page":"105","volume":"4","author":"J Xue","year":"2021","unstructured":"Xue J, Ni H, Wang F, Xu K, Niu M. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. J Interv Med. 2021;4(3):105\u201313.","journal-title":"J Interv Med"},{"key":"1995_CR25","doi-asserted-by":"publisher","first-page":"e20230035","DOI":"10.22575\/interventionalradiology.2023-0035","volume":"10","author":"M Kudo","year":"2024","unstructured":"Kudo M. Systemic therapy combined with locoregional therapy in intermediate-stage hepatocellular carcinoma. Interv Radiol (Higashimatsuyama). 2024;10:e20230035. https:\/\/doi.org\/10.22575\/interventionalradiology.2023-0035.","journal-title":"Interv Radiol (Higashimatsuyama)"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01995-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-01995-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01995-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:08:55Z","timestamp":1784866135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-01995-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-01995-7","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This retrospective study was approved by the Institutional Review Board of the University of Osaka Hospital (IRB #24445). For this type of study formal consent is not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the Institutional Review Board of the University of Osaka Hospital (IRB #24445).","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}